Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure

详细信息    查看全文

• 作者：Melanie Balduin ; Mark Oette ; Martin P. Dä ; umer ; Daniel Hoffmann ; Herbert J. Pfister ; Rolf Kaiser
• 刊名：Journal of Clinical Virology
• 出版年：2009
• 出版时间：May 2009
• 年：2009
• 卷：45
• 期：1
• 页码：34-38
• 全文大小：248 K

文摘

Background and objectives

Minority HIV-1 populations with resistance mutations might result in therapy failure. The prevalence of transmitted minorities in therapy-naïve patients and their influence on the virological outcome of the first-line-therapy need clarification.

Study design

The HIV reverse transcriptase (RT) of 159 therapy-naïve patients from the RESINA-cohort was genotyped. The relative amount of RT-K103N was measured by primer specific PCR. The response to first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-therapy was evaluated.

Results

Bulk-sequencing detected 1 NNRTI mutation (no K103N) in six patients (1.26 % ). K103N minorities were found in 20.1 % of the samples, more frequently in HIV-1 non-B subtypes (40.6 % ) than in subtype B (15.0 % ) (p = 0.0025). NNRTI treatment failed after 12 weeks in 24 % of 17 patients with minority, but only in 15 % of 67 patients without minority.

Conclusions

K103N minorities were found in 20.1 % of the patients, whereas the prevalence of major K103N populations was 3 % in the total RESINA-cohort. K103N minorities were more frequent in non-B subtypes. There is some evidence for a higher risk of NNRTI-treatment failure in patients with K103N minorities; however, the majority of patients with minority underwent a successful first-line-treatment.